| Bioactivity | KRCA-0008 is a selective ALK/Ack1 inhibitor with IC50s of 12 and 4 nM for ALK and Ack1, respectively. KRCA-0008 can be used for the research of cancer[1][2]. | ||||||||||||
| Invitro | KRCA-0008 (0-1000 μM) shows potency to ALK (wt), ALK L1196 M, ALK C1156Y, ALK F1174L, ALK R1275Q and insulin receptor with IC50s of 12, 75, 4, 17, 17 and 210 nM, respectively[1].KRCA-0008 (0-1000 nM; 4 h) inhibits ALK-dependent signaling pathways more potently than crizotinib[2].KRCA-0008 (0-1000 nM; 72 h) induces cell apoptosis[2].KRCA-0008 (0-100 nM; 48 h) affects cell cycle[2]. Cell Proliferation Assay[1] Cell Line: | ||||||||||||
| Name | KRCA-0008 | ||||||||||||
| CAS | 1472795-20-2 | ||||||||||||
| Formula | C30H37ClN8O4 | ||||||||||||
| Molar Mass | 609.12 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
KRCA-0008
CAS: 1472795-20-2 F: C30H37ClN8O4 W: 609.12
KRCA-0008 is a selective ALK/Ack1 inhibitor with IC50s of 12 and 4 nM for ALK and Ack1, respectively. KRCA-0008 can be u
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.